OpenArc Corporate Advisory’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
OpenArc Corporate Advisory's TVTX Position: Q3 2026 in Review
OpenArc Corporate Advisory increased its Travere Therapeutics (TVTX) stake by 0.06% in Q3 2026, buying an estimated $1.28K and bringing the position to 37,521 shares worth $2.21M. The position accounts for 0.02% of the portfolio, ranked #253.
OpenArc Corporate Advisory first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. 344 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- OpenArc Corporate Advisory held 37,521 shares of Travere Therapeutics worth $2.21M as of Q3 2026.
- OpenArc Corporate Advisory bought 21 Travere Therapeutics shares in Q3 2026, an estimated $1.28K.
- Travere Therapeutics made up 0.02% of OpenArc Corporate Advisory's portfolio in Q3 2026, its #253 holding.
- OpenArc Corporate Advisory first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 344 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on OpenArc Corporate Advisory's 13F filing for Q3 2026, filed 21 Oct 2026.